{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:32:41Z","timestamp":1777365161765,"version":"3.51.4"},"reference-count":50,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2023,5,10]]},"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>\n                      To provide accurate figures of the frequency of specific clinical features in ovarian cancer (OC) associated with germline\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      pathogenic variants and to define their relevance in predicting the presence of a germline pathogenic variant in these genes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review of papers published from 1995 to February 2022 was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Data from eligible papers were synthesised through meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-seven papers were reviewed, including a total of 12\u2009886 patients with OC. Among\n                      <jats:italic>BRCA<\/jats:italic>\n                      carriers, 86.4% displayed serous type, 83.3% high grade (G3), 83.7% FIGO (The International Federation of Gynecology and Obstetrics) stage III\/IV, 39.7% age at diagnosis \u226450 years and 18.1% personal breast cancer history, while the frequency of these features in non-carriers resulted significantly lower (p&lt;0.001). The meta-analysis showed that the strongest predictor of\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      pathogenic variants was a personal breast cancer history (OR 5.21, 95% CI 4.02 to 6.55, compared with no previous breast cancer), followed by high grade (OR 2.47, 95% CI 1.97 to 3.10, compared with low\/intermediate grade), serous histotype (OR 2.33, 95% CI 2.07 to 2.64, compared with other histotypes), advanced (III\/IV) FIGO stage (OR 1.89, 95% CI 1.67 to 2.15, compared with stage I\/II) and age at diagnosis \u226450 years (OR 1.20, 95% CI 1.01 to 1.42, compared with &gt;50 years).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The results of this meta-analysis provide data on features increasing the prior probability of finding\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      pathogenic variants that may prove helpful in counselling patients and prioritising testing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42021271815.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jcp-2022-208753","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T13:23:44Z","timestamp":1684848224000},"page":"510-517","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Factors predicting\n                    <i>BRCA1\/2<\/i>\n                    pathogenic variants in patients with ovarian cancer: a systematic review with meta-analysis"],"prefix":"10.1136","volume":"76","author":[{"given":"Giovanni","family":"Innella","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy"},{"name":"Medical Genetics Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3763-9372","authenticated-orcid":false,"given":"Lea","family":"Godino","sequence":"additional","affiliation":[{"name":"Medical Genetics Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Erini","sequence":"additional","affiliation":[{"name":"Medical Genetics Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"De Leo","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy"},{"name":"Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donatella","family":"Santini","sequence":"additional","affiliation":[{"name":"Department of Pathology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Myriam","family":"Perrone","sequence":"additional","affiliation":[{"name":"Medical Genetics Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"},{"name":"Division of Oncologic Gynecology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierandrea","family":"De Iaco","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy"},{"name":"Division of Oncologic Gynecology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Zamagni","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Turchetti","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy"},{"name":"Medical Genetics Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"key":"2025112109115096000_76.8.510.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21387"},{"key":"2025112109115096000_76.8.510.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.8545"},{"key":"2025112109115096000_76.8.510.3","doi-asserted-by":"publisher","DOI":"10.1086\/318787"},{"key":"2025112109115096000_76.8.510.4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10120487","article-title":"Role of BRCA mutations in cancer treatment with Poly(ADP-ribose) polymerase (PARP) inhibitors","volume":"10","author":"Faraoni","year":"2018","journal-title":"Cancers (Basel)"},{"key":"2025112109115096000_76.8.510.5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","article-title":"Genetic\/familial high-risk assessment: Breast, ovarian, and Pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Daly","year":"2021","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"2025112109115096000_76.8.510.6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz062"},{"key":"2025112109115096000_76.8.510.7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.gore.2019.07.007","article-title":"BRCA Mutation in high grade epithelial ovarian cancers","volume":"29","author":"Manchana","year":"2019","journal-title":"Gynecol Oncol Rep"},{"key":"2025112109115096000_76.8.510.8","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/787143","article-title":"BRCA-associated ovarian cancer: From molecular Genetics to risk management","volume":"2014","author":"Girolimetti","year":"2014","journal-title":"Biomed Res Int"},{"key":"2025112109115096000_76.8.510.9","doi-asserted-by":"publisher","DOI":"10.1038\/srep29506"},{"key":"2025112109115096000_76.8.510.10","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2016.135"},{"key":"2025112109115096000_76.8.510.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"2025112109115096000_76.8.510.12","doi-asserted-by":"crossref","unstructured":"Godino L . How to structure excel for systematic review process. Nurse Res 2023:40\u20136.","DOI":"10.7748\/nr.2023.e1866"},{"key":"2025112109115096000_76.8.510.13","first-page":"1","article-title":"AHFMR Alberta Heritage foundation for medical research. Standard quality assessment criteria for evaluating primary research papers from Avariety of fields","volume":"13","author":"Kmet","year":"2004","journal-title":"HTA Initiat"},{"key":"2025112109115096000_76.8.510.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2011.11.014"},{"key":"2025112109115096000_76.8.510.15","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-021-09123-6","article-title":"Assessing frequency and clinical outcomes of BRCA Mutated ovarian cancer in Saudi women","volume":"22","author":"Agha","year":"2022","journal-title":"BMC Cancer"},{"key":"2025112109115096000_76.8.510.16","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.2147\/CMAR.S206817","article-title":"Frequency of Germline mutations in Brca1 and Brca2 in ovarian cancer patients and their effect on treatment outcome","volume":"11","author":"Ashour","year":"2019","journal-title":"Cancer Manag Res"},{"key":"2025112109115096000_76.8.510.17","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1055\/a-1222-0042","article-title":"Prevalence of Brca1 and Brca2 mutations in patients with primary ovarian cancer - does the German checklist for detecting the risk of hereditary breast and ovarian cancer adequately depict the need for consultation? Geburtshilfe Frauenheilkd","volume":"80","author":"Ataseven","year":"2020","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"2025112109115096000_76.8.510.18","doi-asserted-by":"publisher","DOI":"10.1111\/jog.14090"},{"key":"2025112109115096000_76.8.510.19","doi-asserted-by":"crossref","first-page":"85529","DOI":"10.18632\/oncotarget.13456","article-title":"Prevalence and clinical significance of Brca1\/2 Germline and somatic mutations in Taiwanese patients with ovarian cancer","volume":"7","author":"Chao","year":"2016","journal-title":"Oncotarget"},{"key":"2025112109115096000_76.8.510.20","doi-asserted-by":"crossref","unstructured":"Cotrim DP , Ribeiro ARG , Paix\u00e3o D , et al . Prevalence of Brca1 and Brca2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil. BMC Cancer 2019;19. doi:10.1186\/s12885-018-5235-3","DOI":"10.1186\/s12885-018-5235-3"},{"key":"2025112109115096000_76.8.510.21","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.672","article-title":"Comprehensive analysis of serum tumor markers and Brca1\/2 Germline mutations in Chinese ovarian cancer patients","volume":"7","author":"Deng","year":"2019","journal-title":"Mol Genet Genomic Med"},{"key":"2025112109115096000_76.8.510.22","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-000384"},{"key":"2025112109115096000_76.8.510.23","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2017.220"},{"key":"2025112109115096000_76.8.510.24","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1200\/GO.21.00051","article-title":"Prevalence of Brca1 and Brca2 mutations among patients with ovarian, primary peritoneal, and Fallopian tube cancer in India: A multicenter cross-sectional study","volume":"7","author":"Gupta","year":"2021","journal-title":"JCO Glob Oncol"},{"key":"2025112109115096000_76.8.510.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.12.027"},{"key":"2025112109115096000_76.8.510.26","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ygyno.2015.11.001","article-title":"Evaluation of Germline Brca1 and Brca2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients","volume":"141","author":"Hasmad","year":"2016","journal-title":"Gynecol Oncol"},{"key":"2025112109115096000_76.8.510.27","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2018.29.e90","article-title":"Brca1\/2 mutations, including large Genomic Rearrangements, among Unselected ovarian cancer patients in Korea","volume":"29","author":"Kim","year":"2018","journal-title":"J Gynecol Oncol"},{"key":"2025112109115096000_76.8.510.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.07.024"},{"key":"2025112109115096000_76.8.510.29","first-page":"00069","article-title":"BRCA mutations, Homologous DNA repair deficiency, tumor mutational burden, and response to immune Checkpoint inhibition in recurrent ovarian cancer","volume":"4","author":"Liu","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"2025112109115096000_76.8.510.30","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs494"},{"key":"2025112109115096000_76.8.510.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.12.015"},{"key":"2025112109115096000_76.8.510.32","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15166"},{"key":"2025112109115096000_76.8.510.33","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21536"},{"key":"2025112109115096000_76.8.510.34","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2016-103902"},{"key":"2025112109115096000_76.8.510.35","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2017-105140"},{"key":"2025112109115096000_76.8.510.36","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-60149-5","article-title":"Oncologist-led BRCA 'Mainstreaming' in the ovarian cancer clinic: A study of 255 patients and its impact on their management","volume":"10","author":"Rumford","year":"2020","journal-title":"Sci Rep"},{"key":"2025112109115096000_76.8.510.37","doi-asserted-by":"crossref","first-page":"viii63","DOI":"10.1093\/annonc\/mdt315","article-title":"BRCA mutations and outcome in epithelial ovarian cancer (EOC): Experience in ethnically diverse groups","volume":"24 Suppl 8","author":"Safra","year":"2013","journal-title":"Ann Oncol"},{"key":"2025112109115096000_76.8.510.38","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/cncr.29707","article-title":"Brca1 and Brca2 mutations in Japanese patients with ovarian, Fallopian tube, and primary peritoneal cancer","volume":"122","author":"Sakamoto","year":"2016","journal-title":"Cancer"},{"key":"2025112109115096000_76.8.510.39","first-page":"3144","article-title":"Mutational analysis of Brca1 and Brca2 and Clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: Two common founder mutations of Brca1 in Japanese population","volume":"7","author":"Sekine","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2025112109115096000_76.8.510.40","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/ijc.30633","article-title":"Brca1 and Brca2 mutations in ovarian cancer patients from China: Ethnic-related mutations in Brca1 associated with an increased risk of ovarian cancer","volume":"140","author":"Shi","year":"2017","journal-title":"Int J Cancer"},{"key":"2025112109115096000_76.8.510.41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4806"},{"key":"2025112109115096000_76.8.510.42","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/ajco.13520","article-title":"Frequency of Germline Brca1\/2 mutations and association with Clinicopathological characteristics in Turkish women with epithelial ovarian cancer","volume":"18","author":"Sunar","year":"2022","journal-title":"Asia Pac J Clin Oncol"},{"key":"2025112109115096000_76.8.510.43","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-016-0227-x","article-title":"BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study","volume":"9","author":"Unni","year":"2016","journal-title":"J Ovarian Res"},{"key":"2025112109115096000_76.8.510.44","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/jnci\/djz138","article-title":"Universal tumor DNA Brca1\/2 testing of ovarian cancer: Prescreening Parpi treatment and genetic predisposition","volume":"112","author":"Tomao","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"2025112109115096000_76.8.510.45","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000001065"},{"key":"2025112109115096000_76.8.510.46","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00295","article-title":"Germline and somatic Brca1\/2 mutations in 172 Chinese women with epithelial ovarian cancer","volume":"10","author":"You","year":"2020","journal-title":"Front Oncol"},{"key":"2025112109115096000_76.8.510.47","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-016-2966-x","article-title":"Germline mutations in Brca1 and Brca2 in epithelial ovarian cancer patients in Brazil","volume":"16","author":"Maistro","year":"2016","journal-title":"BMC Cancer"},{"key":"2025112109115096000_76.8.510.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2012.01.008"},{"key":"2025112109115096000_76.8.510.49","doi-asserted-by":"publisher","DOI":"10.1097\/01.pgp.0000101080.35393.16"},{"key":"2025112109115096000_76.8.510.50","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0b013e3181c042b6"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp-2022-208753","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:12:01Z","timestamp":1763745121000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp-2022-208753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":50,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,7,19]]},"published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1136\/jcp-2022-208753"],"URL":"https:\/\/doi.org\/10.1136\/jcp-2022-208753","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,23]]}}}